






NGS for Discovery. ddPCR™ Solutions for Decisions Support.

From Discovery to Monitoring:
A Hybrid NGS + ddPCR Workflow

NGS Alone Can Slow Decisions

NGS delivers powerful mutation discovery, but long turnaround times, complex analysis, and sensitivity limits can delay confirmation and follow-up. When timing matters, sequencing alone may not provide the speed or precision needed for rapid decision-making.¹⁻³


NGS Challenges¹⁻³

- 
 Long turnaround times delay treatment
- 
 High costs limit repeat testing
- 
 Complex bioinformatics and data storage
- 
 Batching requirements increase wait times
- 
 Lower sensitivity at very low VAFs

Why Combine ddPCR Technology and NGS?

NGS enables broad mutation discovery. ddPCR technology provides rapid, highly sensitive confirmation and follow-up analysis of known variants. Together, they form a hybrid workflow that reduces complexity, accelerates turnaround, and supports confident decisions without repeated sequencing.¹⁻³

Integrate ddPCR Technology Into Your NGS Workflow for Faster, More Confident Answers



Choosing the Right Tool After Variant Discovery¹⁻³

Workflow Need	Best Method	Why
Identify unknown mutations	NGS	Broad genomic discovery
Confirm detected variants	ddPCR technology	Orthogonal validation
Monitor mutation burden over time	ddPCR technology	Precise quantification
Multiplexing	NGS ddPCR technology	Screen hundreds of genes Screen <50 genes*
Detect ultra-low frequency variants	ddPCR technology	Higher sensitivity ≤0.01% VAF
Routine longitudinal testing	ddPCR technology	Faster and cost-efficient
Simplicity	ddPCR technology	Ease of use, same day results

*Up to 20 targets per run for discrimination, and higher multiplexing for screening.

References

- Szeto S et al. (2025). Performance comparison of Droplet Digital PCR and next-generation sequencing for circulating tumor DNA detection in non-metastatic rectal cancer. *Cancer Med* 14, e70943.
- Ouh YT et al. (2026). Diagnostic accuracy of the Droplet Digital PCR POLE mutation test in endometrial cancer: comparison with Sanger sequencing and NGS. *J Gynecol Oncol* 37, e83.
- Mittal AK et al. (2024). Economic implications of ddPCR and NGS-based noninvasive prenatal testing for fetal aneuploidy screening. *Int J Public Health Sci* 13, 1809-1818.



For Research Use Only. Not for use in diagnostic procedures.

Bio-Rad and ddPCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.

©2026 Bio-Rad Laboratories, Inc.

Bulletin 3903 Ver A

26-884200 0426